The European Medicines Agency (EMA) publishes open letters, usually in response to contributions and feedback from stakeholders.
Replies to open letters from Members of the European Parliament concerning the marketing authorisations of mRNA COVID-19 vaccines
Follow-up reply to Members of the European Parliament regarding mRNA COVID-19 vaccines
English (EN) (205.28 KB - PDF)
Reply to Members of the European Parliament regarding mRNA COVID-19 vaccines
English (EN) (223.19 KB - PDF)
Reply in follow up to the COVI exchange of views on 27 March 2023
EMA reply in follow up to the COVI exchange of views on 27 March 2023
English (EN) (220.21 KB - PDF)
Reply to open letter from Members of the European Parliament's letter on psychedelic-assisted therapies
EMA reply to a letter from Members of the European Parliament, Mr Agius Saliba, Ms Ries, Mr Duda, Mr Biedroń, Ms Cerdas and Ms Metz concerning psychedelic-assisted therapies
English (EN) (121.47 KB - PDF)
Reply to open letter from Members of the European Parliament concerning COVID-19 vaccines
Reply to open letter from ‘Doctors for COVID ethics’ concerning COVID-19 vaccines
Reply to open letter to ‘Doctors for COVID ethics’ concerning COVID-19 vaccines
English (EN) (191.99 KB - PDF)
Reply to open letter concerning COVID-19 vaccines
Reply to open letter concerning vaccines for COVID-19
English (EN) (132.69 KB - PDF)
Letter from the chairs of EMA's Management Board to Guido Rasi at the end of his term as EMA's Executive Director
Letter from the chairs of EMA's Management Board to Guido Rasi at the end of his term as EMA's Executive Director
English (EN) (98.84 KB - PDF)
Reply to open letter concerning the transparency and evaluation of vaccines for COVID-19
Reply to open letter concerning the transparency and evaluation of vaccines for COVID-19
English (EN) (231.26 KB - PDF)
Response to the European Ombudsman concerning transparency and independence of EMA's work in supporting the development and evaluation of COVID-19 medicines
Reply to the European Ombudsman’s letter concerning transparency and independence of the work of the European Medicines Agency in supporting the development and evaluation of COVID-19 medicines
English (EN) (192.91 KB - PDF)
Response to the Institute for Quality and Efficiency in Health Care (IQWiG) and the Cochrane Collaboration on transparency of COVID-19-related activities
European Medicines Agency response to IQWIG on transparency of COVID-19 related activities
European Medicines Agency response to IQWIG on transparency of COVID-19 related activities
English (EN) (131.35 KB - PDF)
Response to European Ombudsman regarding pre-submission activities
European Medicines Agency second response to European Ombudsman regarding pre-submission activities
English (EN) (174.5 KB - PDF)
European Medicines Agency first response to European Ombudsman regarding pre-submission activities
English (EN) (165.74 KB - PDF)
Response to Nordic Cochrane Centre on safety review of human papillomavirus vaccines
EMA response to Nordic Cochrane letter on human papillomavirus (HPV) vaccines - Conflict of interest issues of Executive Director
English (EN) (74.72 KB - PDF)
EMA response to Nordic Cochrane letter on EMA response to Nordic Cochrane letter on human papillomavirus (HPV) vaccines - Maladministration
English (EN) (198.13 KB - PDF)
Clarifying the adaptive pathways concept
EMA response to a letter from a group of scientists clarifying the concept of adaptive pathways
English (EN) (123.75 KB - PDF)
Response to European Ombudsman explaining redaction rules
Letter to European Ombudsman
Agency responds to European Ombudsman
English (EN) (811.95 KB - PDF)
Response to European Ombudsman on clinical trial data transparency
European Medicines Agency letter to European Ombudsman regarding proactive publication of and access to clinical trial data
English (EN) (1.06 MB - PDF)
Letter to Member of European Parliament requesting correction
Letter from the European Medicines Agency to Ms M Rivasi regarding Dr Xavier Kurz
English (EN) (62.29 KB - PDF)
Response to British Medical Journal editorial on the new Agency
An open letter to the Editor of the British Medical Journal
English (EN) (24.67 KB - PDF)